Research programme: fusion protein cancer therapeutics - Aida PharmaceuticalsAlternative Names: Vasostatin-Apo2L
Latest Information Update: 16 Jul 2016
At a glance
- Originator Aida Pharmaceuticals; Shanghai Qiaer Bio-Technology
- Developer Shanghai Qiaer Bio-Technology
- Class Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 15 Mar 2007 Preclinical trials in Solid tumours in China (unspecified route)